Boehler Brings Global Commercial Leadership From BioNTech’s mRNA Vaccine Rollout to Accelerate clock.bio’s Rejuvenation Biology Platform and Advance Therapies That Extend Healthspan CAMBRIDGE, England – August 27, 2025 – clock.bio, the rejuvenation biology company developing therapies to reverse aging and extend healthspan, today announced the appointment of Dr. Michael Boehler, former BioNTech executive, as Chief Business...
News
Our CEO speaks at BioAge’s podcast about technology, progress and vision at clock.bio
Markus Gstöttner, our CEO, was hosted by BioAge Lab’s podcast Translating Ageing, where he discussed clock.bio’s innovative approach to identifying genes and pathways involved in cellular rejuvenation. Markus also shared about his background and his vision to shape the company in order to translate clock.bio’s technology into clinical applications. Read more here
clock.bio’s Atlas of rejuvenation
On October 2024, clock.bio was featured in Endpoint. Read more here
clock.bio raises 5.3M for rejuvenation roadmap
On October 2024, clock.bio was featured in Business Weekly. Read more here
New funding round brings 5.3M for clock.bio
On October 2024, clock.bio was featured in Genetic Engineering & Biotechnology News. Read more here
clock.bio decodes Atlas of Rejuvenation
On October 2024, clock.bio was featured in Longevity Technology. Read more here
clock.bio to slow ageing with 5.3M funding for Atlas of rejuvenation
On October 2024, clock.bio was featured in Cambridge Independent. Read more here
clock.bio raises 5.3M in seed funding round
On October 2024, clock.bio was featured in Business Wire. Read more here
clock.bio raises 4m to enter anti-ageing race
On September 2023, clock.bio was featured in Cambridge Independent. Read more here
clock.bio aims to extend health span by 20 years
On August 2023, clock.bio was featured in Endpoint. Read more here
Clock.bio launches aiming to decode rejuvenation biology
On August 2023, clock.bio was featured in Business Wire. Read more here